Therapeutic Advances in Gastroenterology (Jun 2023)

Brief communication: global temporal trends in the efficacy of clarithromycin-based regimens for the treatment of infection

  • Steven F. Moss,
  • William D. Chey,
  • Patrick Daniele,
  • Corey Pelletier,
  • Rinu Jacob,
  • Gabriel Tremblay,
  • Elizabeth Hubscher,
  • Eckhard Leifke,
  • Peter Malfertheiner

DOI
https://doi.org/10.1177/17562848231167284
Journal volume & issue
Vol. 16

Abstract

Read online

Background: Helicobacter pylori eradication rates achieved with clarithromycin-based triple therapies are declining due to antibiotic resistance, but data regarding temporal changes in efficacy with these eradication therapies are scarce. Objective: To evaluate the efficacy of clarithromycin-based triple eradication regimens over time. Design: A comprehensive literature review and time-trend analysis. Data sources and methods: Bibliographies of recently published systematic literature reviews were searched and supplemented with a targeted literature review conducted using Medline and Embase databases and ProQuest from conception to May 2021. Studies reporting H. pylori eradication rates of clarithromycin-based triple therapies were included and temporal trends were estimated using a random-effects model. Results: Eradication rates for triple therapies containing proton pump inhibitors (PPIs), clarithromycin, and amoxicillin showed a significant decline over the past 23 years ( p = 0.0315). However, this decline was not significant when eradication rates achieved with vonoprazan-based triple therapy were included ( p = 0.3910). Conclusion: Vonoprazan-based triple therapy partially mitigated the decline in eradication rates seen with PPI-based triple therapy, likely due to more powerful acid suppression of vonoprazan.